Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial by Hagop Kantarjian,

Slides:



Advertisements
Similar presentations
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
Advertisements

Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CML (Percent Responding 9 or 10)
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.
Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Shah N et al. Proc ASH 2010;Abstract 206.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Ellen K. Ritchie Clinical Director, Richard T. Silver MPN Center
Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results.
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
Cortes JE et al. Proc ASCO 2010;Abstract 6502.
by Timothy P. Hughes, and David M. Ross
Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.
Monitoring Milestones in Patients With Chronic Myeloid Leukemia
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib by Jorge.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
Protease inhibitors potentiate chemotherapy-induced neutropenia
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International.
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.
Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients.
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.
Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia  Vivian.
Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.
1Kantarjian HM et al. Lancet Oncol 2011;12:
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?  Elias Jabbour, MD, Jorge E. Cortes,
High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid.
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML by Jorge E. Cortes, Martin S. Tallman, Gary.
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Presentation transcript:

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial by Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, and Neil Shah Blood Volume 109(12):5143-5150 June 15, 2007 ©2007 by American Society of Hematology

Duration of major cytogenetic response. Hagop Kantarjian et al. Blood 2007;109:5143-5150 ©2007 by American Society of Hematology

Time to treatment failure. Hagop Kantarjian et al. Blood 2007;109:5143-5150 ©2007 by American Society of Hematology

Progression-free survival. Hagop Kantarjian et al. Blood 2007;109:5143-5150 ©2007 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.